Novamind (NM: CSE) Is Building the Infrastructure Required for a Regulated Psychedelics Industry

The global behavioural health market size is expected to reach approximately US$ 245 billion by 2027 and  estimated to grow at CAGR of 2.5 % over the forecast time frame 2020 to  2027. As a consequence of the increasing incidence of mental health  disorders, global demand for mental health facilities is increasing. Psychedelics are going to go through parabolic, paradigm-shifting  growth because of their ability to treat anxiety and depression amongst  other things Novamind is a leading mental health company specialized in  psychedelic medicine, building the infrastructure required for a  regulated psychedelics industry. Highlights: Rapidly expanding a network of outpatient mental health clinics and research sites 4 clinics in Utah, 1 more anticipated this quarter Provides ketamine-assisted psychotherapy and Spravato™ (esketamine) treatments; Ketamine treatment volume grew 90% from 2019 to 2020 During the same period, total Spravato™ treatments rose 400% Positioned to facilitate MDMA and psilocybin therapy post-FDA approval Building centers of excellence for future approved psychedelic treatments Approximately CAN$1,900,000 in 2019 revenue Strong insider ownership (32.3%)